Loading…
Cognitive protection of incretin‐based therapies in patients with type 2 diabetes mellitus: A systematic review and meta‐analysis based on clinical studies
Aims/introduction Cognitive dysfunction, including mild cognitive impairment and dementia, is increasingly recognized as an important complication of type 2 diabetes mellitus. The aims of the preset study was to investigate the cognitive protection of incretin‐based therapies, including glucagon‐lik...
Saved in:
| Published in: | Journal of diabetes investigation 2023-07, Vol.14 (7), p.864-873 |
|---|---|
| Main Authors: | , , , , |
| Format: | Article |
| Language: | English |
| Subjects: | |
| Citations: | Items that this one cites Items that cite this one |
| Online Access: | Get full text |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| cited_by | cdi_FETCH-LOGICAL-c5345-302c81a57d31b069e7ddc5d6f6ef818e5d4f0437fb06dba01910182be56eda3 |
|---|---|
| cites | cdi_FETCH-LOGICAL-c5345-302c81a57d31b069e7ddc5d6f6ef818e5d4f0437fb06dba01910182be56eda3 |
| container_end_page | 873 |
| container_issue | 7 |
| container_start_page | 864 |
| container_title | Journal of diabetes investigation |
| container_volume | 14 |
| creator | Chai, Sanbao Liu, Fengqi Yu, Shuqing Yang, Zhirong Sun, Feng |
| description | Aims/introduction
Cognitive dysfunction, including mild cognitive impairment and dementia, is increasingly recognized as an important complication of type 2 diabetes mellitus. The aims of the preset study was to investigate the cognitive protection of incretin‐based therapies, including glucagon‐like peptide‐1 receptor agonists and dipeptidyl peptidase‐4 inhibitors, in patients with type 2 diabetes mellitus.
Materials and Methods
PubMed, EMBASE, Cochrane library, Web of Science and PsycINFO were searched from the inception through 17 January 2023 for randomized controlled trials and cohort studies on the association between incretin‐based therapies and cognitive function. A total of 15 studies were finally included in our systematic review, and eight of which were incorporated into our meta‐analysis.
Results
Pooled results showed that the Mini‐Mental State Examination score in incretin‐based therapy groups was increased by 1.20 compared with the control group (weighted mean difference 1.20, 95% confidence interval 0.39–2.01). The results of eight studies assessed by the Newcastle Ottawa Quality Assessment Scale and the Cochrane Collaboration's tool, and the quality of the eight studies were at a relatively high level. Egger's regression did not show significant publication bias.
Conclusions
Current evidence shows that incretin‐based therapies might be more effective, when compared with the other hypoglycemic drugs, for cognitive improvement in patients with type 2 diabetes mellitus.
Cognitive dysfunction is recognized as an complication of type 2 diabetes mellitus. Incretin has emerged as a potential therapeutic agent for Alzheimer's disease. Incretin has a protective effect on cognitive function in type 2 diabetes mellitus patients. |
| doi_str_mv | 10.1111/jdi.14015 |
| format | article |
| fullrecord | <record><control><sourceid>proquest_doaj_</sourceid><recordid>TN_cdi_doaj_primary_oai_doaj_org_article_652d1a4213eb49689a72d4ff63726b14</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><doaj_id>oai_doaj_org_article_652d1a4213eb49689a72d4ff63726b14</doaj_id><sourcerecordid>2828349230</sourcerecordid><originalsourceid>FETCH-LOGICAL-c5345-302c81a57d31b069e7ddc5d6f6ef818e5d4f0437fb06dba01910182be56eda3</originalsourceid><addsrcrecordid>eNp1ks1uEzEQgFcIRKvSAy-ALHGBQ1r_rdfLBVXhL6gSB7hbXns2cbRZL7Y3UW69cuMVeLU-CW62RBQJX2x5Pn8zHk1RPCf4guR1ubbugnBMykfFKcUczwih_PHxTMRJcR7jGufFpBSielqcsIrwSkp5Wvya-2XvktsCGoJPYJLzPfItcr0JkFx_e_Oz0REsSisIenAQcwgNOjnoU0Q7l1Yo7Qe4vflBkXW6gZSRDXSdS2N8g65Q3McEm_zAoABbBzuke5uJpLNb97rbRxfRlCTnNp3rndEdimm0Od2z4kmruwjn9_tZ8fXD-2_zT7PrLx8X86vrmSkZL2cMUyOJLivLSINFDZW1prSiFdBKIqG0vMWcVW0O2kZjUhNMJG2gFGA1OysWk9V6vVZDcBsd9sprpw4XPiyVDvkLHShRUks0p4RBw2sha13RLG8Fq6hoCM-ut5NrGJsNWJMbFXT3QPow0ruVWvqtIphKUUmWDa_uDcF_HyEmtXHR5J7qHvwYFZUE16Sih2Qv_0HXfgy5q3cUlYzXlOFMvZ4oE3yMAdpjNQSruzFSeYzUYYwy--Lv8o_kn6HJwOUE7FwH-_-b1Od3i0n5G7vD1ww</addsrcrecordid><sourcetype>Open Website</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2828349230</pqid></control><display><type>article</type><title>Cognitive protection of incretin‐based therapies in patients with type 2 diabetes mellitus: A systematic review and meta‐analysis based on clinical studies</title><source>Open Access: PubMed Central</source><source>Publicly Available Content Database (Proquest) (PQ_SDU_P3)</source><source>Open Access: Wiley-Blackwell Open Access Journals</source><creator>Chai, Sanbao ; Liu, Fengqi ; Yu, Shuqing ; Yang, Zhirong ; Sun, Feng</creator><creatorcontrib>Chai, Sanbao ; Liu, Fengqi ; Yu, Shuqing ; Yang, Zhirong ; Sun, Feng</creatorcontrib><description>Aims/introduction
Cognitive dysfunction, including mild cognitive impairment and dementia, is increasingly recognized as an important complication of type 2 diabetes mellitus. The aims of the preset study was to investigate the cognitive protection of incretin‐based therapies, including glucagon‐like peptide‐1 receptor agonists and dipeptidyl peptidase‐4 inhibitors, in patients with type 2 diabetes mellitus.
Materials and Methods
PubMed, EMBASE, Cochrane library, Web of Science and PsycINFO were searched from the inception through 17 January 2023 for randomized controlled trials and cohort studies on the association between incretin‐based therapies and cognitive function. A total of 15 studies were finally included in our systematic review, and eight of which were incorporated into our meta‐analysis.
Results
Pooled results showed that the Mini‐Mental State Examination score in incretin‐based therapy groups was increased by 1.20 compared with the control group (weighted mean difference 1.20, 95% confidence interval 0.39–2.01). The results of eight studies assessed by the Newcastle Ottawa Quality Assessment Scale and the Cochrane Collaboration's tool, and the quality of the eight studies were at a relatively high level. Egger's regression did not show significant publication bias.
Conclusions
Current evidence shows that incretin‐based therapies might be more effective, when compared with the other hypoglycemic drugs, for cognitive improvement in patients with type 2 diabetes mellitus.
Cognitive dysfunction is recognized as an complication of type 2 diabetes mellitus. Incretin has emerged as a potential therapeutic agent for Alzheimer's disease. Incretin has a protective effect on cognitive function in type 2 diabetes mellitus patients.</description><identifier>ISSN: 2040-1116</identifier><identifier>EISSN: 2040-1124</identifier><identifier>DOI: 10.1111/jdi.14015</identifier><identifier>PMID: 37147888</identifier><language>eng</language><publisher>Japan: John Wiley & Sons, Inc</publisher><subject>Alzheimer's disease ; Bias ; Clinical trials ; Cognition ; Cognition & reasoning ; Cognitive ability ; Cognitive function ; Cohort analysis ; Collaboration ; Confidence intervals ; Dementia ; Dementia disorders ; Diabetes ; Diabetes mellitus (non-insulin dependent) ; Diabetes Mellitus, Type 2 - chemically induced ; Diabetes Mellitus, Type 2 - complications ; Diabetes Mellitus, Type 2 - drug therapy ; Dipeptidyl-Peptidase IV Inhibitors - adverse effects ; GLP-1 receptor agonists ; Glucagon ; Glucagon-like peptide 1 ; Glucagon-Like Peptide-1 Receptor - agonists ; Hemoglobin ; Humans ; Hypoglycemic Agents - adverse effects ; Incretins - therapeutic use ; Incretin‐based therapy ; Insulin ; Meta-analysis ; Original ; Peptides ; Quality control ; Questionnaires ; Sensitivity analysis ; Statistical significance ; Systematic review ; Type 2 diabetes</subject><ispartof>Journal of diabetes investigation, 2023-07, Vol.14 (7), p.864-873</ispartof><rights>2023 The Authors. published by Asian Association for the Study of Diabetes (AASD) and John Wiley & Sons Australia, Ltd.</rights><rights>2023 The Authors. Journal of Diabetes Investigation published by Asian Association for the Study of Diabetes (AASD) and John Wiley & Sons Australia, Ltd.</rights><rights>2023. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c5345-302c81a57d31b069e7ddc5d6f6ef818e5d4f0437fb06dba01910182be56eda3</citedby><cites>FETCH-LOGICAL-c5345-302c81a57d31b069e7ddc5d6f6ef818e5d4f0437fb06dba01910182be56eda3</cites><orcidid>0000-0002-8746-518X</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.proquest.com/docview/2828349230/fulltextPDF?pq-origsite=primo$$EPDF$$P50$$Gproquest$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.proquest.com/docview/2828349230?pq-origsite=primo$$EHTML$$P50$$Gproquest$$Hfree_for_read</linktohtml><link.rule.ids>230,314,727,780,784,885,11562,25753,27924,27925,37012,37013,44590,46052,46476,53791,53793,75126</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/37147888$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Chai, Sanbao</creatorcontrib><creatorcontrib>Liu, Fengqi</creatorcontrib><creatorcontrib>Yu, Shuqing</creatorcontrib><creatorcontrib>Yang, Zhirong</creatorcontrib><creatorcontrib>Sun, Feng</creatorcontrib><title>Cognitive protection of incretin‐based therapies in patients with type 2 diabetes mellitus: A systematic review and meta‐analysis based on clinical studies</title><title>Journal of diabetes investigation</title><addtitle>J Diabetes Investig</addtitle><description>Aims/introduction
Cognitive dysfunction, including mild cognitive impairment and dementia, is increasingly recognized as an important complication of type 2 diabetes mellitus. The aims of the preset study was to investigate the cognitive protection of incretin‐based therapies, including glucagon‐like peptide‐1 receptor agonists and dipeptidyl peptidase‐4 inhibitors, in patients with type 2 diabetes mellitus.
Materials and Methods
PubMed, EMBASE, Cochrane library, Web of Science and PsycINFO were searched from the inception through 17 January 2023 for randomized controlled trials and cohort studies on the association between incretin‐based therapies and cognitive function. A total of 15 studies were finally included in our systematic review, and eight of which were incorporated into our meta‐analysis.
Results
Pooled results showed that the Mini‐Mental State Examination score in incretin‐based therapy groups was increased by 1.20 compared with the control group (weighted mean difference 1.20, 95% confidence interval 0.39–2.01). The results of eight studies assessed by the Newcastle Ottawa Quality Assessment Scale and the Cochrane Collaboration's tool, and the quality of the eight studies were at a relatively high level. Egger's regression did not show significant publication bias.
Conclusions
Current evidence shows that incretin‐based therapies might be more effective, when compared with the other hypoglycemic drugs, for cognitive improvement in patients with type 2 diabetes mellitus.
Cognitive dysfunction is recognized as an complication of type 2 diabetes mellitus. Incretin has emerged as a potential therapeutic agent for Alzheimer's disease. Incretin has a protective effect on cognitive function in type 2 diabetes mellitus patients.</description><subject>Alzheimer's disease</subject><subject>Bias</subject><subject>Clinical trials</subject><subject>Cognition</subject><subject>Cognition & reasoning</subject><subject>Cognitive ability</subject><subject>Cognitive function</subject><subject>Cohort analysis</subject><subject>Collaboration</subject><subject>Confidence intervals</subject><subject>Dementia</subject><subject>Dementia disorders</subject><subject>Diabetes</subject><subject>Diabetes mellitus (non-insulin dependent)</subject><subject>Diabetes Mellitus, Type 2 - chemically induced</subject><subject>Diabetes Mellitus, Type 2 - complications</subject><subject>Diabetes Mellitus, Type 2 - drug therapy</subject><subject>Dipeptidyl-Peptidase IV Inhibitors - adverse effects</subject><subject>GLP-1 receptor agonists</subject><subject>Glucagon</subject><subject>Glucagon-like peptide 1</subject><subject>Glucagon-Like Peptide-1 Receptor - agonists</subject><subject>Hemoglobin</subject><subject>Humans</subject><subject>Hypoglycemic Agents - adverse effects</subject><subject>Incretins - therapeutic use</subject><subject>Incretin‐based therapy</subject><subject>Insulin</subject><subject>Meta-analysis</subject><subject>Original</subject><subject>Peptides</subject><subject>Quality control</subject><subject>Questionnaires</subject><subject>Sensitivity analysis</subject><subject>Statistical significance</subject><subject>Systematic review</subject><subject>Type 2 diabetes</subject><issn>2040-1116</issn><issn>2040-1124</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2023</creationdate><recordtype>article</recordtype><sourceid>24P</sourceid><sourceid>PIMPY</sourceid><sourceid>DOA</sourceid><recordid>eNp1ks1uEzEQgFcIRKvSAy-ALHGBQ1r_rdfLBVXhL6gSB7hbXns2cbRZL7Y3UW69cuMVeLU-CW62RBQJX2x5Pn8zHk1RPCf4guR1ubbugnBMykfFKcUczwih_PHxTMRJcR7jGufFpBSielqcsIrwSkp5Wvya-2XvktsCGoJPYJLzPfItcr0JkFx_e_Oz0REsSisIenAQcwgNOjnoU0Q7l1Yo7Qe4vflBkXW6gZSRDXSdS2N8g65Q3McEm_zAoABbBzuke5uJpLNb97rbRxfRlCTnNp3rndEdimm0Od2z4kmruwjn9_tZ8fXD-2_zT7PrLx8X86vrmSkZL2cMUyOJLivLSINFDZW1prSiFdBKIqG0vMWcVW0O2kZjUhNMJG2gFGA1OysWk9V6vVZDcBsd9sprpw4XPiyVDvkLHShRUks0p4RBw2sha13RLG8Fq6hoCM-ut5NrGJsNWJMbFXT3QPow0ruVWvqtIphKUUmWDa_uDcF_HyEmtXHR5J7qHvwYFZUE16Sih2Qv_0HXfgy5q3cUlYzXlOFMvZ4oE3yMAdpjNQSruzFSeYzUYYwy--Lv8o_kn6HJwOUE7FwH-_-b1Od3i0n5G7vD1ww</recordid><startdate>202307</startdate><enddate>202307</enddate><creator>Chai, Sanbao</creator><creator>Liu, Fengqi</creator><creator>Yu, Shuqing</creator><creator>Yang, Zhirong</creator><creator>Sun, Feng</creator><general>John Wiley & Sons, Inc</general><general>John Wiley and Sons Inc</general><general>Wiley</general><scope>24P</scope><scope>WIN</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7T5</scope><scope>7TM</scope><scope>7X7</scope><scope>7XB</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>H94</scope><scope>K9.</scope><scope>M0S</scope><scope>PIMPY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>7X8</scope><scope>5PM</scope><scope>DOA</scope><orcidid>https://orcid.org/0000-0002-8746-518X</orcidid></search><sort><creationdate>202307</creationdate><title>Cognitive protection of incretin‐based therapies in patients with type 2 diabetes mellitus: A systematic review and meta‐analysis based on clinical studies</title><author>Chai, Sanbao ; Liu, Fengqi ; Yu, Shuqing ; Yang, Zhirong ; Sun, Feng</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c5345-302c81a57d31b069e7ddc5d6f6ef818e5d4f0437fb06dba01910182be56eda3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2023</creationdate><topic>Alzheimer's disease</topic><topic>Bias</topic><topic>Clinical trials</topic><topic>Cognition</topic><topic>Cognition & reasoning</topic><topic>Cognitive ability</topic><topic>Cognitive function</topic><topic>Cohort analysis</topic><topic>Collaboration</topic><topic>Confidence intervals</topic><topic>Dementia</topic><topic>Dementia disorders</topic><topic>Diabetes</topic><topic>Diabetes mellitus (non-insulin dependent)</topic><topic>Diabetes Mellitus, Type 2 - chemically induced</topic><topic>Diabetes Mellitus, Type 2 - complications</topic><topic>Diabetes Mellitus, Type 2 - drug therapy</topic><topic>Dipeptidyl-Peptidase IV Inhibitors - adverse effects</topic><topic>GLP-1 receptor agonists</topic><topic>Glucagon</topic><topic>Glucagon-like peptide 1</topic><topic>Glucagon-Like Peptide-1 Receptor - agonists</topic><topic>Hemoglobin</topic><topic>Humans</topic><topic>Hypoglycemic Agents - adverse effects</topic><topic>Incretins - therapeutic use</topic><topic>Incretin‐based therapy</topic><topic>Insulin</topic><topic>Meta-analysis</topic><topic>Original</topic><topic>Peptides</topic><topic>Quality control</topic><topic>Questionnaires</topic><topic>Sensitivity analysis</topic><topic>Statistical significance</topic><topic>Systematic review</topic><topic>Type 2 diabetes</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Chai, Sanbao</creatorcontrib><creatorcontrib>Liu, Fengqi</creatorcontrib><creatorcontrib>Yu, Shuqing</creatorcontrib><creatorcontrib>Yang, Zhirong</creatorcontrib><creatorcontrib>Sun, Feng</creatorcontrib><collection>Open Access: Wiley-Blackwell Open Access Journals</collection><collection>Wiley Journals</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Immunology Abstracts</collection><collection>Nucleic Acids Abstracts</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni)</collection><collection>ProQuest Central</collection><collection>ProQuest Central Essentials</collection><collection>AUTh Library subscriptions: ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Publicly Available Content Database (Proquest) (PQ_SDU_P3)</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><collection>DOAJ Directory of Open Access Journals</collection><jtitle>Journal of diabetes investigation</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Chai, Sanbao</au><au>Liu, Fengqi</au><au>Yu, Shuqing</au><au>Yang, Zhirong</au><au>Sun, Feng</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Cognitive protection of incretin‐based therapies in patients with type 2 diabetes mellitus: A systematic review and meta‐analysis based on clinical studies</atitle><jtitle>Journal of diabetes investigation</jtitle><addtitle>J Diabetes Investig</addtitle><date>2023-07</date><risdate>2023</risdate><volume>14</volume><issue>7</issue><spage>864</spage><epage>873</epage><pages>864-873</pages><issn>2040-1116</issn><eissn>2040-1124</eissn><abstract>Aims/introduction
Cognitive dysfunction, including mild cognitive impairment and dementia, is increasingly recognized as an important complication of type 2 diabetes mellitus. The aims of the preset study was to investigate the cognitive protection of incretin‐based therapies, including glucagon‐like peptide‐1 receptor agonists and dipeptidyl peptidase‐4 inhibitors, in patients with type 2 diabetes mellitus.
Materials and Methods
PubMed, EMBASE, Cochrane library, Web of Science and PsycINFO were searched from the inception through 17 January 2023 for randomized controlled trials and cohort studies on the association between incretin‐based therapies and cognitive function. A total of 15 studies were finally included in our systematic review, and eight of which were incorporated into our meta‐analysis.
Results
Pooled results showed that the Mini‐Mental State Examination score in incretin‐based therapy groups was increased by 1.20 compared with the control group (weighted mean difference 1.20, 95% confidence interval 0.39–2.01). The results of eight studies assessed by the Newcastle Ottawa Quality Assessment Scale and the Cochrane Collaboration's tool, and the quality of the eight studies were at a relatively high level. Egger's regression did not show significant publication bias.
Conclusions
Current evidence shows that incretin‐based therapies might be more effective, when compared with the other hypoglycemic drugs, for cognitive improvement in patients with type 2 diabetes mellitus.
Cognitive dysfunction is recognized as an complication of type 2 diabetes mellitus. Incretin has emerged as a potential therapeutic agent for Alzheimer's disease. Incretin has a protective effect on cognitive function in type 2 diabetes mellitus patients.</abstract><cop>Japan</cop><pub>John Wiley & Sons, Inc</pub><pmid>37147888</pmid><doi>10.1111/jdi.14015</doi><tpages>873</tpages><orcidid>https://orcid.org/0000-0002-8746-518X</orcidid><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 2040-1116 |
| ispartof | Journal of diabetes investigation, 2023-07, Vol.14 (7), p.864-873 |
| issn | 2040-1116 2040-1124 |
| language | eng |
| recordid | cdi_doaj_primary_oai_doaj_org_article_652d1a4213eb49689a72d4ff63726b14 |
| source | Open Access: PubMed Central; Publicly Available Content Database (Proquest) (PQ_SDU_P3); Open Access: Wiley-Blackwell Open Access Journals |
| subjects | Alzheimer's disease Bias Clinical trials Cognition Cognition & reasoning Cognitive ability Cognitive function Cohort analysis Collaboration Confidence intervals Dementia Dementia disorders Diabetes Diabetes mellitus (non-insulin dependent) Diabetes Mellitus, Type 2 - chemically induced Diabetes Mellitus, Type 2 - complications Diabetes Mellitus, Type 2 - drug therapy Dipeptidyl-Peptidase IV Inhibitors - adverse effects GLP-1 receptor agonists Glucagon Glucagon-like peptide 1 Glucagon-Like Peptide-1 Receptor - agonists Hemoglobin Humans Hypoglycemic Agents - adverse effects Incretins - therapeutic use Incretin‐based therapy Insulin Meta-analysis Original Peptides Quality control Questionnaires Sensitivity analysis Statistical significance Systematic review Type 2 diabetes |
| title | Cognitive protection of incretin‐based therapies in patients with type 2 diabetes mellitus: A systematic review and meta‐analysis based on clinical studies |
| url | http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-29T13%3A10%3A44IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_doaj_&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Cognitive%20protection%20of%20incretin%E2%80%90based%20therapies%20in%20patients%20with%20type%E2%80%892%20diabetes%20mellitus:%20A%20systematic%20review%20and%20meta%E2%80%90analysis%20based%20on%20clinical%20studies&rft.jtitle=Journal%20of%20diabetes%20investigation&rft.au=Chai,%20Sanbao&rft.date=2023-07&rft.volume=14&rft.issue=7&rft.spage=864&rft.epage=873&rft.pages=864-873&rft.issn=2040-1116&rft.eissn=2040-1124&rft_id=info:doi/10.1111/jdi.14015&rft_dat=%3Cproquest_doaj_%3E2828349230%3C/proquest_doaj_%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c5345-302c81a57d31b069e7ddc5d6f6ef818e5d4f0437fb06dba01910182be56eda3%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=2828349230&rft_id=info:pmid/37147888&rfr_iscdi=true |